DDInter1652 DDInter1623
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotarix is a live attenuated vaccine containing the 89-12 human strain.[Label] Rotavirus vaccines are 90% effective in protecting against severe rotavirus infection.
Rotavirus vaccine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Budesonide
Rotavirus vaccine {u} may lead to a major life threatening interaction when taken with {v} Carmustine
Rotavirus vaccine {u} may lead to a major life threatening interaction when taken with {v} Sarilumab
Rotavirus vaccine may cause a moderate interaction that could exacerbate diseases when taken with Budesonide
Rotavirus vaccine may lead to a major life threatening interaction when taken with Carmustine
Rotavirus vaccine may lead to a major life threatening interaction when taken with Sarilumab